2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
134 hedge funds and large institutions have $544M invested in 2seventy bio in 2022 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 27 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
30% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 27
5% more funds holding
Funds holding: 128 → 134 (+6)
9% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 32
33% less capital invested
Capital invested by funds: $816M → $544M (-$273M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$26.8M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$20.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$20.9M |
| 4 |
RI
RTW Investments
New York
|
+$20.9M |
| 5 |
AC
Armistice Capital
New York
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.14M |
| 2 |
Goldman Sachs
New York
|
-$6.64M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.68M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$1.99M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.98M |
TSVT Hedge Fund Activity: Q1 2022 in Review
134 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q1 2022, worth a combined $544M — down 33% from $816M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TSVT positions and 27 closed out — a net gain of 8 holders — while 35 added to existing stakes and 32 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $26.8M. The largest seller was Vanguard Group, cutting an estimated $8.14M.
- 134 institutional investors held 2seventy bio (TSVT) as of Q1 2022, up from 128 in Q4 2021.
- Funds reported $544M of 2seventy bio stock for Q1 2022, down 33% quarter-over-quarter.
- 35 funds opened new 2seventy bio positions in Q1 2022 and 27 closed out, a net change of +8 holders.
- The largest 2seventy bio buyer in Q1 2022 was EcoR1 Capital, an estimated $26.8M added.
- The largest 2seventy bio seller in Q1 2022 was Vanguard Group, an estimated $8.14M sold.
Based on aggregated 13F filings for Q1 2022.